Fliptin Dosage/Direction for Use

The recommended dose of sitagliptin is 100 mg once daily as monotherapy or as combination therapy with metformin or a PPARγ agonist (e.g., thiazolidinediones), metformin and sulfonylurea, stable dose of insulin (with or without metformin). Sitagliptin can be taken with or without food.
When used in combination with metformin or a PPARγ agonist, the dose of metformin or PPARγ agonist should be maintained, and sitagliptin administered concomitantly.
When sitagliptin is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycemia.
Special populations: Patients with renal impairment: Because there is a dosage adjustment based upon renal function, assessment of renal function is recommended prior to initiation of sitagliptin and periodically thereafter.
For patients with mild renal impairment (eGFR ≥60 ml/minute/1.73 m² to <90 ml/minute/1.73 m²), no dosage adjustment for sitagliptin is required.
For patients with moderate renal impairment (eGFR ≥45 ml/minute/1.73 m² to <60 ml/minute/1.73 m²), no dosage adjustment for sitagliptin is required.
For patients with moderate renal impairment (eGFR ≥30 ml/minute/1.73 m² to <45 ml/minute/1.73 m²), the dose of sitagliptin is 50 mg once daily.
For patients with severe renal impairment (eGFR ≥15 ml/minute/1.73 m² to <30 ml/minute/1.73 m²) or with end-stage renal disease (ESRD) (eGFR <15 ml/minute/1.73 m²), including those requiring hemodialysis or peritoneal dialysis, the dose of sitagliptin is 25 mg once daily. Sitagliptin may be administered without regard to the timing of dialysis.